Successful treatment of catastrophic antiphospholipid antibody syndrome associated with MALT lymphoma by autologous hematopoietic stem cell transplantation

Internal Medicine

Volumn 56, Issue 10, 2017, Pages 1207-1212

  Oka, Satoko ^a   Ono, Kazuo ^a   Nohgawa, Masaharu ^a  

^a JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Catastrophic antiphospholipid antibody syndrome (CAPS); Extranodal marginal zone lymphoma (MALT lymphoma); Hematopoietic stem cell transplantation (HSCT)

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CD20 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; HAPTOGLOBIN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISOLONE; RANIMUSTINE; RITUXIMAB; VINCRISTINE;

ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME; DISEASE ASSOCIATION; DYSPNEA; FEMALE; FEVER; HEMIPLEGIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVASCULAR HEMOLYSIS; LUNG BIOPSY; LUNG INFILTRATE; LYMPHADENOPATHY; MARGINAL ZONE LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; THORAX RADIOGRAPHY; THROMBOPLASTIN TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; AUTOTRANSPLANTATION; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, B-CELL, MARGINAL ZONE; REMISSION; TREATMENT OUTCOME;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 85019215872     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.56.7806     Document Type: Article

References (16)

1. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80: 355-377, 2001.
2. Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530-534, 2003.
3. Miesbach W, Asherson RA, Cervera R, et al. The catastrophic antiphospholipid (Asherson’s) syndrome and malignancies. Autoimmun Rev 6: 94-97, 2006.
4. Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 33: 355-357, 2006.
5. Marmont AM. New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation. Annu Rev Med 51: 115-134, 2000.
6. Miesbach W. Malignancies and catastrophic anti-phospholipid syndrome. Clin Rev Allergy Immunol 36: 91-97, 2009.
7. Lim W. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2013: 675-680, 2013.
8. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46: 1019-1027, 2002.
9. Olalla JI, Ortín M, Hermida G, et al. Disappearance of lupus anticoagulant after allogeneic bone marrow transplantation. Bone Marrow Transplant 23: 83-85, 1999.
10. Owaidah TM, Maghrabi K, Elkarouri MA, Al Mohareeb F, Al Harthi A, Al Zahrani H. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature. Bone Marrow Transplant 46: 597-600, 2011.
11. Asherson RA, Espinosa G, Menahem S, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 37: 366-372, 2008.
12. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 20-27, 2006.
13. Maeshima AM, Taniguchi H, Toyoda K, et al. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. Br J Haematol 174: 923-931, 2016.
14. Meyer AH, Stroux A, Lerch K, et al. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol 25: 210-215, 2014.
15. Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin’s lymphoma. Leuk Lymphoma 45: 315-320, 2004.
16. Li L, Bierman P, Vose J, Loberiza F, Armitage JO, Bociek RG. High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 11: 253-256, 2011.